Cancer Information Highlights, December 18, 2019

Cancer Information Highlights, December 18, 2019

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI Surgery for Recurrent Ovarian Cancer Does Not Help Survival   Read about a large clinical trial that suggests that additional surgery after ovarian cancer has returned does not help women live longer. Immunotherapy Drug Improves Outcomes for Some Children with Relapsed Leukemia   New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab (Blincyto) is better than standard chemotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned after treatment.  Advances in Thyroid Cancer Research NCI-funded researchers are working to advance our understanding of thyroid cancer. Learn about recent research results and progress in the treatment of thyroid cancer, plus ongoing projects to study its causes. People with Cancer Discuss Use of Genomic Data in Their Care   NCI recently sponsored a scientific workshop where people with cancer, survivors, researchers, and advocates exchanged ideas about personal genomic data, issues related to privacy, and data sharing. Opportunities in Cancer Research: Strengthening the Research Enterprise Having a community of researchers from diverse backgrounds and at all levels of expertise strengthens cancer research and its translation to patient care. Learn how NCI continues to support the development of the cancer research workforce, infrastructure, and small business innovation in this chapter of the NCI Annual Plan & Budget Proposal for Fiscal Year 2021. KRAS Inhibitor Shows Promise in Early Trial KRAS is a cancer-related protein that was once thought “undruggable.” Read about the first KRAS inhibitor to enter a clinical trial and some early results. Targeted Therapy for Lung Cancer with EGRF Mutations Improves Survival   Updated results from a large clinical trial show that one of the newest EGFR-targeted drugs, osimertinib (Tagrisso), is more effective than earlier therapies of this type.

Also of Interest Contact Us for Help Information specialists at NCI’s contact center, the Cancer Information Service (CIS), are available to help answer your cancer-related questions whether you are a person with cancer, family member or friend, health care provider, or researcher. Obesity and Cancer Learn more about overweight and obesity, such as how they are measured, their related health risks, their related cancer risks, why overweight and obesity increase the risk of certain cancers, and how they affect life after cancer.